Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
2.130
+0.060 (2.90%)
At close: Aug 26, 2026, 4:00 PM EDT
2.130
0.00 (0.00%)
After-hours: Aug 26, 2026, 4:52 PM EDT
Palisade Bio Employees
Palisade Bio had 14 employees as of December 31, 2025. The number of employees increased by 6 or 75.00% compared to the previous year.
Employees
14
Change (1Y)
6
Growth (1Y)
75.00%
Revenue / Employee
$35,714
Profits / Employee
-$2,281,500
Market Cap
371.20M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 14 | 6 | 75.00% |
| Dec 31, 2024 | 8 | -1 | -11.11% |
| Dec 31, 2023 | 9 | -3 | -25.00% |
| Dec 31, 2022 | 12 | -1 | -7.69% |
| Dec 31, 2021 | 13 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Abeona Therapeutics | 226 |
| Lyell Immunopharma | 161 |
| Sutro Biopharma | 128 |
| Zentalis Pharmaceuticals | 106 |
| SAB Biotherapeutics | 86 |
| Agenus | 81 |
| InflaRx | 65 |
| Immuneering | 57 |
PALI News
- 16 days ago - Palisade Bio reports Q2 EPS (22c), consensus (5c) - TheFly
- 16 days ago - Palisade Bio Quarterly report: Q2 2026 - Filings
- 16 days ago - Palisade Bio Earnings release: Q2 2026 - Filings
- 25 days ago - Palisade Bio Slides: Corporate presentation - Filings
- 4 weeks ago - Palisade Bio initiated with an Outperform at Oppenheimer - TheFly
- 6 weeks ago - Palisade Bio management to meet with Piper Sandler - TheFly
- 6 weeks ago - Palisade Bio to Participate in the Leerink Partners Therapeutics Forum - GlobeNewsWire
- 2 months ago - Palisade Bio receives FDA clearance to start ulcerative colitis study - TheFly